Key structural requirements of benzamide derivatives for histone deacetylase inhibition : design, synthesis and biological evaluation
Background: Histone deacetylase inhibitors (HDACIs) are important as anticancer agents. Objective: This study aimed to investigate some key structural features of HDACIs via the design, synthesis and biological evaluation of novel benzamide-based derivatives. Methods: Novel structures, designed using a molecular modification approach, were synthesized and biologically evaluated. Results: The results indicated that a subset of molecules with CH3/NH2 at R2 position possess selective antiproliferative activity. However, only those with an NH2 group showed HDACI activity. Importantly, the shorter the molecule length, the stronger HDACI. Among all, 7j was the most potent HDAC1-3 inhibitor and antiproliferative compound. Conclusion: The results of the present investigation could provide valuable structural knowledge applicable for the development of the HDACIs and benzamide-based antiproliferative agents in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - (2024) vom: 16. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheshmazar, Narges [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Revised 16.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.4155/fmc-2023-0122 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371131219 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371131219 | ||
| 003 | DE-627 | ||
| 005 | 20240416233733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2023-0122 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM371131219 | ||
| 035 | |a (NLM)38623995 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheshmazar, Narges |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Key structural requirements of benzamide derivatives for histone deacetylase inhibition |b design, synthesis and biological evaluation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Background: Histone deacetylase inhibitors (HDACIs) are important as anticancer agents. Objective: This study aimed to investigate some key structural features of HDACIs via the design, synthesis and biological evaluation of novel benzamide-based derivatives. Methods: Novel structures, designed using a molecular modification approach, were synthesized and biologically evaluated. Results: The results indicated that a subset of molecules with CH3/NH2 at R2 position possess selective antiproliferative activity. However, only those with an NH2 group showed HDACI activity. Importantly, the shorter the molecule length, the stronger HDACI. Among all, 7j was the most potent HDAC1-3 inhibitor and antiproliferative compound. Conclusion: The results of the present investigation could provide valuable structural knowledge applicable for the development of the HDACIs and benzamide-based antiproliferative agents in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a QSAR | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a histone deacetylase inhibitors | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a molecular dynamics simulation | |
| 650 | 4 | |a structure modification | |
| 650 | 4 | |a synthesis | |
| 700 | 1 | |a Hamzeh-Mivehroud, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmati, Salar |e verfasserin |4 aut | |
| 700 | 1 | |a Abolhasani, Hoda |e verfasserin |4 aut | |
| 700 | 1 | |a Heidari, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Charoudeh, Hojjatollah Nozad |e verfasserin |4 aut | |
| 700 | 1 | |a Zessin, Matthes |e verfasserin |4 aut | |
| 700 | 1 | |a Schutkowski, Mike |e verfasserin |4 aut | |
| 700 | 1 | |a Sippl, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Dastmalchi, Siavoush |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g (2024) vom: 16. Apr. |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2023-0122 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 04 | ||